Regentis Biomaterials (RGNT) Advances European Commercial Launch Plans for GelrinC
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Regentis Biomaterials (RGNT) Advances European Commercial Launch Plans for GelrinC
LOS ANGELES, CA - June 8, 2026 (NEWMEDIAWIRE) - Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begi…
Regentis Biomaterials to Start European Surgeon Training for GelrinC in Q3 2026
Regentis Biomaterials (NYSE American: RGNT) has announced plans to initiate European surgeon training activities in the third quarter of 2026 as part of its preparations for the commercial rollout of GelrinC, its CE Mark-approved treatment for knee cartilage lesions. The hands-on program is designed to provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospit…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
